Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model

ConclusionsAtogepant and rimegepant were both unable to meet generally accepted cost-effectiveness thresholds< 150,0000/QALY. Additional studies are needed to better guide decision making regarding oral CGRPs ’ place in therapy.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research